Young Journalists Club | Latest news of Iran and world

News ID: 43200
Publish Date: 12:43 - 19 August 2019
TEHRAN, August 19 - Novartis (NOVN.S) plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker’s decision to delay informing regulators until after the treatment’s approval.

Novartis to answer U.S. Senate demand for data manipulation detailsTEHRAN, Young Journalists Club (YJC) -“We are planning to respond but we haven’t submitted yet,” a spokesman said on Monday.

U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.

Novartis, which won approval for Zolgensma in May — more than a month before it told the Food and Drug Administration of the alleged data fraud — has terminated several scientists amid an internal investigation.

Source: Reuters

Your Comment
Name:
Email:
* Comment:
* captcha: